Purpose: To evaluate the influence of atrial fibrillation in the natural history of hypertrophic cardiomyopathy.

Methods: Eighty-eight patients under ambulatory treatment were studied. Most of them presented the asymmetric type of hypertrophic cardiomyopathy (87.5%). Group I (77 cases) was formed by patients who had never had atrial fibrillation and group II (11 cases) by those who had this arrhythmia paroxysmal or established.

Results: In group I, with ages 48.02 +/- 14.82 years, left atrial dimensions 4.21 +/- 0.66 cm, there was one sudden death; 69 were treated by clinical means and 7 by surgery; no patient developed thromboembolism neither cardiac failure. In group II, with ages 58.02 +/- 11.04 years and left atrial dimension 5.32 +/- 0.45 cm, there were 4 deaths, 4 thromboembolisms and 3 with cardiac failure; all received only clinical treatment, having improved in clinical status in 71.42% after amiodarone therapy.

Conclusion: Atrial fibrillation was present in 12.5%, mostly in the asymmetric type, and in patients after 5th decade, all of them with enlarged left atrium (> 4.7 cm), with highest morbidity (thromboembolism and cardiac failure) and mortality. Among the survivors, amiodarone therapy improved functional class in 71.42%.

Download full-text PDF

Source

Publication Analysis

Top Keywords

atrial fibrillation
16
cardiac failure
12
fibrillation natural
8
natural history
8
history hypertrophic
8
asymmetric type
8
group cases
8
group ages
8
years left
8
left atrial
8

Similar Publications

Introduction: The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.

View Article and Find Full Text PDF

Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches.

Int J Med Sci

January 2025

Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China.

Elevated lipoprotein(a) [Lp(a)] levels are increasingly recognized as a significant risk factor for cardiovascular diseases and may also contribute to atrial fibrillation (AF). This review investigated the indirect mechanisms through which Lp(a) may influence AF, including proatherogenic, prothrombotic, and proinflammatory pathways. Traditional lipid-lowering therapies, such as lifestyle modifications and statins, have limited effects on Lp(a) levels.

View Article and Find Full Text PDF

Comparison of Catheter Ablation in Patients with Paroxysmal Non-valvular Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction.

Int J Med Sci

January 2025

Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China.

The efficacy of radiofrequency ablation (RFA) in patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) has been established, but the efficacy and safety of cryoballoon ablation (CBA) and pulsed field ablation (PFA) remain unclear. This retrospective cohort study included 223 patients with paroxysmal non-valvular AF and HFpEF who underwent their first AF ablation between January 2017 and December 2021 and were divided into RFA (n = 77), CBA (n = 127), and PFA (n = 19) groups. After a mean follow-up of 11.

View Article and Find Full Text PDF

Background Atrial high-rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are indicative of future clinical atrial fibrillation (AF) and stroke risk. This study aimed to investigate the prevalence of AHREs among Thai patients with CIED implantation and identify associated risk factors. Methods A retrospective observational study enrolled 278 CIED patients with AHREs lasting five minutes to 24 hours, with an average atrial rate ≥ 175 bpm, excluding known clinical AF at device implantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!